Northwestern Medicine scientists have identified a key driver of chemotherapy resistance in advanced ovarian cancer, according to a study published in the Journal of Clinical Investigation. Ovarian ...
A potential target for experimental drugs that block PRMT5 - a naturally occurring enzyme some tumors rely more on for survival - has been identified by researchers with the Fralin Biomedical Research ...
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy. PRMT5 ...
SAN DIEGO, April 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced initial preclinical results evaluating its investigational ...
Epigenetic alterations represent heritable yet reversible structural changes in histone or DNA. Protein arginine methylation, a common post-translational modification, is mediated by the protein ...
Researchers at the Advanced Science Research Center (ASRC) at The Graduate Center of The City University of New York report that they have discovered the role of a protein known as PRMT5 in the ...
Shanghai Apeiron Biotechnology Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results